Metabolic acidosis is defined by a primary decrease in serum bicarbonate (HCO₃⁻) with resultant acidemia (pH <7.35), and is classified by the anion gap into high anion gap metabolic acidosis (HAGMA) and non-anion gap (hyperchloremic) metabolic acidosis (NAGMA). [1-3] The distinction is the single most important step in narrowing the differential and guiding management.
The following algorithmic approach to metabolic acidosis evaluation is shown below:
1. History
- Onset and tempo: Acute (hours) vs. subacute/chronic (days–weeks); rapid onset suggests toxic ingestion, DKA, or lactic acidosis
- Symptom characterization: Dyspnea (Kussmaul respirations), nausea/vomiting, abdominal pain, confusion, lethargy, fatigue
- Triggers: Recent illness/infection, missed insulin doses, alcohol binge, new medications, fasting/starvation, diarrhea, surgery
- Ingestion history: Intentional or accidental ingestion of methanol, ethylene glycol, aspirin, iron, isoniazid, toluene
- Medication review: Metformin, topiramate, acetazolamide, SGLT2 inhibitors, antiretrovirals (tenofovir), NSAIDs
- Important negatives: Absence of diarrhea, no recent IV fluid resuscitation (rules out dilutional/hyperchloremic acidosis), no urinary diversion history [3]
2. Alarm Features
- pH <7.10–7.20: Severe acidemia with risk of hemodynamic collapse, arrhythmias, impaired cardiac contractility, and diaphragmatic dysfunction [4-5]
- Kussmaul respirations with altered mental status or obtundation
- Hemodynamic instability: Hypotension, tachycardia, signs of shock (suggests lactic acidosis from sepsis or hemorrhage)
- Visual disturbances: Pathognomonic for methanol poisoning — requires emergent treatment [6]
- Seizures or coma: Suggests toxic alcohol ingestion, severe uremia, or profound acidemia
- Oliguria/anuria: Suggests AKI or advanced CKD as the etiology
- Fruity breath odor: DKA or isopropyl alcohol; garlic odor suggests organophosphate [3][7]
- Calcium oxalate crystalluria: Ethylene glycol poisoning
3. Medications
Medications that cause metabolic acidosis
- HAGMA: Metformin (lactic acidosis, especially with renal impairment), aspirin/salicylates, iron, isoniazid, linezolid, nucleoside reverse transcriptase inhibitors
- NAGMA: Carbonic anhydrase inhibitors (topiramate, acetazolamide, zonisamide), SGLT2 inhibitors (euglycemic DKA), amphotericin B, spironolactone, amiloride [8-9]
- Combination risk: Concomitant metformin + carbonic anhydrase inhibitors increases lactic acidosis risk [8]
Common treatments
- IV sodium bicarbonate (see Treatment Plan)
- Fomepizole (toxic alcohols)
- Insulin + fluids (DKA)
- Oral sodium bicarbonate or sodium citrate (chronic CKD-related acidosis) [10-11]
Contraindicated medications
- Metformin should be held in acute illness with AKI, sepsis, or hemodynamic instability
- Potassium-based alkali (e.g., potassium bicarbonate) is contraindicated in CKD due to hyperkalemia risk [12]
4. Diet
- Acute setting: Dietary management is not a priority; focus on IV correction
- Chronic metabolic acidosis (CKD): Increased intake of fruits and vegetables (alkaline-rich, plant-dominant diets) reduces net endogenous acid production and is comparable to oral sodium bicarbonate in small RCTs [11][13]
- Avoid high-acid-load diets: Excessive animal protein, processed foods increase acid burden in CKD
- Hydration: Aggressive IV fluid resuscitation in DKA and lactic acidosis; use balanced crystalloids (LR) over normal saline to avoid iatrogenic hyperchloremic acidosis [2]
- Alcohol cessation: Critical in alcoholic ketoacidosis and recurrent lactic acidosis
5. Review of Systems
- Respiratory: Dyspnea, tachypnea, Kussmaul breathing
- GI: Nausea, vomiting, abdominal pain (DKA, uremia), diarrhea (bicarbonate loss)
- Neurologic: Confusion, lethargy, visual changes (methanol), seizures, coma
- Renal/GU: Oliguria, polyuria/polydipsia (DKA), hematuria (rhabdomyolysis)
- Musculoskeletal: Muscle weakness, myalgias (rhabdomyolysis, severe acidemia)
- Cardiovascular: Palpitations, chest pain (arrhythmia risk from hyperkalemia)
6. Collateral History and Family History
- Collateral: Witnesses to ingestion, medication bottles at scene, access to antifreeze/windshield washer fluid, alcohol use history, insulin compliance
- Psychiatric history: Intentional ingestion of toxic substances
- Family history: Type 1 diabetes, inherited metabolic disorders (organic acidemias in pediatrics), familial RTA
- Social context: Homelessness (methanol/hand sanitizer ingestion), substance use, occupational exposures
7. Risk Factors
- Diabetes mellitus (DKA, metformin-associated lactic acidosis)
- Chronic kidney disease (decreased acid excretion, most common cause of chronic metabolic acidosis) [11]
- Sepsis/shock (lactic acidosis — accounts for ~50% of HAGMA cases) [3]
- Alcohol use disorder (alcoholic ketoacidosis, toxic alcohol ingestion)
- Heart failure (poor perfusion → lactic acidosis; diuretic-related electrolyte shifts)
- Liver disease (impaired lactate clearance)
- Large-volume NS resuscitation (iatrogenic hyperchloremic acidosis)
- Diarrheal illness (bicarbonate loss → NAGMA)
- Rhabdomyolysis (massive cell lysis)
8. Differential Diagnosis
The anion gap is the pivotal diagnostic branch point: [1][3]
High Anion Gap Metabolic Acidosis (HAGMA) — Mnemonic: GOLD MARRK [3]
- Glycols (ethylene glycol, propylene glycol)
- 5-Oxoproline (pyroglutamic acid, chronic acetaminophen use)
- L-Lactate (shock, sepsis, mesenteric ischemia, seizures, liver failure)
- D-Lactate (short bowel syndrome)
- Methanol
- Aspirin (salicylates)
- Renal failure (advanced CKD/ESRD)
- Rhabdomyolysis
- Ketoacidosis (diabetic, alcoholic, starvation)
Non-Anion Gap (Hyperchloremic) Metabolic Acidosis (NAGMA) [3]
- GI bicarbonate loss: Diarrhea, pancreatic/biliary fistula, ureteral diversion
- Renal tubular acidosis (Types 1, 2, 4)
- Carbonic anhydrase inhibitors: Topiramate, acetazolamide
- Large-volume normal saline infusion (dilutional)
- Early renal failure
Cannot-miss diagnoses
- Toxic alcohol ingestion (methanol, ethylene glycol) — delayed diagnosis is often fatal [6][14]
- Sepsis-related lactic acidosis
- Salicylate toxicity (mixed respiratory alkalosis + HAGMA)
- Cyanide or carbon monoxide poisoning
9. Past Medical History
- Diabetes: Type 1 (DKA risk), Type 2 (metformin-associated lactic acidosis, euglycemic DKA with SGLT2i)
- CKD/ESRD: Baseline bicarbonate, dialysis schedule, missed sessions
- Prior episodes of DKA or acidosis
- Surgical history: Short bowel syndrome (D-lactic acidosis), ureterosigmoidostomy (NAGMA)
- Psychiatric history: Prior suicide attempts, access to toxins
- Chronic liver disease: Impaired lactate metabolism
10. Physical Exam
- Vital signs: Tachypnea/Kussmaul respirations, tachycardia, hypotension (shock), fever (sepsis)
- General: Level of consciousness (GCS), signs of dehydration (dry mucous membranes, poor skin turgor)
- HEENT: Fruity/acetone breath (DKA), visual acuity testing (methanol), pupil exam
- Cardiovascular: Irregular rhythm (hyperkalemia-related arrhythmia), signs of poor perfusion
- Pulmonary: Deep, labored breathing pattern; crackles (pulmonary edema)
- Abdomen: Tenderness (pancreatitis, mesenteric ischemia, DKA-related ileus)
- Skin: Mottling (shock), livedo reticularis, track marks (substance use)
- Neurologic: Mental status, focal deficits, asterixis (uremia) [3]
11. Lab Studies
Initial workup
- ABG or VBG: pH, pCO₂, HCO₃⁻ (VBG is acceptable for pH and HCO₃⁻ screening; ABG needed for precise pCO₂ and oxygenation) [4]
- BMP: Na⁺, K⁺, Cl⁻, HCO₃⁻, BUN, creatinine, glucose
- Anion gap = Na⁺ − (Cl⁻ + HCO₃⁻); normal ~12 ± 4 mEq/L. Always correct for albumin: add 2.5 mEq/L per 1 g/dL decrease in albumin below 4 g/dL [3]
- Serum lactate: Essential — the anion gap has <80% sensitivity for detecting elevated lactate [3]
- Serum ketones (beta-hydroxybutyrate preferred over urine ketones)
- Serum osmolality (measured) and osmolal gap (measured − calculated): Gap >10 mOsm/kg suggests toxic alcohol [7]
Targeted labs based on clinical suspicion
- Salicylate and acetaminophen levels (all intentional ingestions)
- Ethylene glycol and methanol levels (if available)
- Serum albumin (for AG correction)
- Urinalysis (calcium oxalate crystals in ethylene glycol; ketones)
- Urine anion gap = (Na⁺ + K⁺) − Cl⁻ for NAGMA workup: negative = GI loss; positive = RTA [3]
- CK (rhabdomyolysis), LFTs, lipase, blood cultures (sepsis)
Delta-delta (gap-gap) analysis: Compare ΔAG to ΔHCO₃⁻ to unmask concurrent metabolic alkalosis or additional NAGMA [3]
12. Imaging
- Chest X-ray: Evaluate for pulmonary edema, pneumonia (sepsis source), aspiration
- CT head: If altered mental status, concern for toxic ingestion with CNS effects
- CT abdomen/pelvis: If abdominal pain with concern for mesenteric ischemia, pancreatitis, or surgical pathology
- Imaging is not routinely required for straightforward DKA or diarrhea-related acidosis
13. Special Tests
- Anion Gap Calculator (displayed above) — the cornerstone diagnostic tool
- Osmolal gap: Calculated osmolality = 2(Na⁺) + glucose/18 + BUN/2.8 + ethanol/4.6; gap >10 mOsm/kg is abnormal [7]
- Delta-delta analysis: ΔAG/ΔHCO₃⁻ ratio — in ketoacidosis expect ~1:1; in lactic acidosis expect ~1:0.6 [3]
- Urine anion gap and urine osmolal gap: For NAGMA differentiation [3]
- Point-of-care glucose and beta-hydroxybutyrate: Rapid DKA assessment
- Wood's lamp on urine: Fluorescence may suggest ethylene glycol (unreliable)
- Toxicology screen: Urine drug screen, serum ethanol
14. ECG
ECG is essential in metabolic acidosis, primarily to evaluate for hyperkalemia-related changes:
- Peaked T waves (earliest sign, K⁺ ~5.5–6.5 mEq/L)
- PR prolongation → P wave flattening/loss (K⁺ ~6.5–7.5 mEq/L)
- QRS widening (K⁺ ~7.0–8.0 mEq/L) — most predictive of serious adverse events [15-17]
- Sine wave pattern → VF/asystole (K⁺ >10 mEq/L)
- Brugada-like pattern: Can be unmasked by acidemia and hyperkalemia
- QTc prolongation: May occur with concurrent electrolyte derangements
- ECG changes have low sensitivity for hyperkalemia and do not reliably correlate with specific K⁺ levels — always check serum potassium [17]
15. Assessment
Severity stratification
- Mild: pH 7.30–7.35, HCO₃⁻ 15–22 mEq/L — often manageable outpatient if etiology is benign
- Moderate: pH 7.20–7.30, HCO₃⁻ 10–15 mEq/L — requires close monitoring, likely inpatient
- Severe: pH <7.20, HCO₃⁻ <10 mEq/L — life-threatening; ICU-level care [4-5]
Key clinical pearls
- Severe acidemia (pH <7.20) causes impaired cardiac contractility, arrhythmias, vasodilation, and diaphragmatic dysfunction [5]
- A "normal" anion gap in a hypoalbuminemic patient may mask a significant HAGMA — always correct for albumin [3]
- Salicylate toxicity classically presents as a mixed respiratory alkalosis + HAGMA
- Euglycemic DKA (SGLT2 inhibitors) may present with normal glucose but significant ketoacidosis [19]
- Lactic acidosis from sepsis is associated with increased mortality — likely reflecting disease severity rather than the acidemia itself [2]
16. Treatment Plan
Initial stabilization (all causes)
- ABCs, IV access, continuous monitoring
- Treat the underlying cause — this is the most important intervention [2][20]
- Aggressive IV fluid resuscitation (balanced crystalloids preferred)
- Correct electrolytes, especially potassium (acidosis shifts K⁺ extracellularly; correction of acidosis will drop K⁺)
Cause-specific treatment
- DKA: IV insulin (start 1–2 hours after fluids), aggressive fluid resuscitation, potassium repletion, monitor glucose and beta-hydroxybutyrate hourly [19]
- Lactic acidosis: Volume resuscitation, vasopressors, source control for sepsis; bicarbonate is controversial (see below)
- Toxic alcohols: Fomepizole 15 mg/kg IV loading dose (preferred over ethanol); hemodialysis indicated for severe acidosis (pH ≤7.15), methanol/EG levels >50 mg/dL, visual changes, seizures, coma, or AKI [6][21-22]
- Salicylate toxicity: IV sodium bicarbonate for urine alkalinization (target urine pH 7.5–8.0); hemodialysis for levels >100 mg/dL, severe acidemia, AKI, or CNS symptoms
- Alcoholic ketoacidosis: IV dextrose-containing fluids + thiamine
- NAGMA from diarrhea: Volume and electrolyte repletion
- RTA: Oral alkali supplementation (sodium bicarbonate or sodium citrate)
Sodium bicarbonate therapy
- Cardiac arrest: 1–2 mEq/kg IV push initially, then 50 mEq every 5–10 min guided by ABG [23]
- Non-arrest severe acidemia: 2–5 mEq/kg IV over 4–8 hours; target HCO₃⁻ ~20 mEq/L by end of day 1 (avoid full correction in 24 hours to prevent rebound alkalosis) [23]
- BICARICU-2 trial (2025): In critically ill patients with severe metabolic acidemia (pH ≤7.20) and moderate-to-severe AKI, sodium bicarbonate infusion reduced the need for kidney replacement therapy. The BICARICU-1 trial showed a mortality benefit in the AKI subgroup (46% vs. 63%) [5]
- Routine use in lactic acidosis without AKI is not supported — focus on treating the underlying cause [2][24]
Chronic CKD-related acidosis
- Oral sodium bicarbonate (start 650 mg TID, titrate to HCO₃⁻ ≥22 mEq/L) [10-11]
- Dietary modification with plant-dominant diets [11][13]
Hemodialysis indications (summarized)
17. Disposition
Admit (ICU)
- pH <7.20 or rapidly worsening acidemia
- Hemodynamic instability or shock
- Toxic alcohol ingestion requiring fomepizole ± hemodialysis
- Severe DKA (pH <7.0, HCO₃⁻ <10, altered mental status, hemodynamic instability)
- Need for kidney replacement therapy
- Respiratory failure or impending respiratory fatigue
Admit (floor/telemetry)
- Moderate acidemia (pH 7.20–7.30) requiring IV treatment
- DKA with stable hemodynamics responding to treatment
- Hyperkalemia requiring monitoring
- New AKI with acidosis
Observation
- Mild DKA responding rapidly to treatment
- Mild acidosis from diarrheal illness with adequate oral intake
Discharge
- Mild chronic NAGMA with known stable etiology (e.g., RTA on alkali therapy, stable CKD)
- Resolved mild acidosis from self-limited cause (e.g., gastroenteritis) with normal vital signs and adequate oral intake
18. Follow Up / Return Precautions
- Follow-up timing: 24–48 hours for discharged patients with resolved mild acidosis; 1–2 weeks for chronic CKD-related acidosis adjustments
- Return immediately for: Recurrent vomiting/diarrhea with inability to tolerate fluids, confusion or altered mental status, worsening dyspnea, chest pain, palpitations, decreased urine output, visual changes
- Patient counseling:
- DKA: Sick-day rules, never stop insulin, monitor glucose closely during illness
- CKD: Medication adherence, dietary modifications, avoid nephrotoxins
- Toxic ingestion: Psychiatric follow-up if intentional; poison-proofing if accidental
- Expected recovery: DKA typically resolves within 12–24 hours with appropriate treatment; lactic acidosis resolves with correction of underlying cause; chronic CKD-related acidosis requires ongoing management [2][19]
- Monitoring: Repeat BMP with bicarbonate level at follow-up; renal function trending in AKI
References
1. Acid-Base Interpretation: A Practical Approach. — Morikawa MJ, Ganesh PR. American Family Physician. 2025.
2. Acid-Base Disorders in the Critically Ill Patient. — Achanti A, Szerlip HM. Clinical Journal of the American Society of Nephrology : CJASN. 2023.
3. Physiological Approach to Assessment of Acid–Base Disturbances. — Berend K, de Vries AP, Gans RO. The New England Journal of Medicine. 2014.
4. Peripheral Venous Blood Gas Analysis for the Diagnosis of Respiratory Failure, Hypercarbia and Metabolic Disturbance in Adults. — Byrne AL, Pace NL, Thomas PS, et al. The Cochrane Database of Systematic Reviews. 2025.
5. Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury. — Jung B, Jabaudon M, De Jong A, et al. The Journal of the American Medical Association. 2025.
6. Toxic Alcohols. — Kraut JA, Mullins ME. The New England Journal of Medicine. 2018.
7. Initial Management of Ingestions of Toxic Substances. — Kulig K. The New England Journal of Medicine. 1992.
8. FDA Drug Label. — Updated date: 2023-01-18. Food and Drug Administration.
9. FDA Drug Label. — Updated date: 2026-04-25. Food and Drug Administration.
10. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. — Navaneethan SD, Bansal N, Cavanaugh KL, et al. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation. 2025.
11. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. — Kidney International. 2024.
12. Veverimer Versus Placebo in Patients With Metabolic Acidosis Associated With Chronic Kidney Disease: A Multicentre, Randomised, Double-Blind, Controlled, Phase 3 Trial. — Wesson DE, Mathur V, Tangri N, et al. Lancet. 2019.
13. Effects of Dietary Interventions for Metabolic Acidosis in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. — Mahboobi S, Mollard R, Tangri N, et al. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2025.
14. High Risk and Low Prevalence Diseases: Toxic Alcohol Ingestion. — Inman B, Maddry JK, Ng PC, Koyfman A, Long B. The American Journal of Emergency Medicine. 2023.
15. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
16. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.
17. Potassium Disorders: Hypokalemia and Hyperkalemia. — Kim MJ, Valerio C, Knobloch GK. American Family Physician. 2023.
18. The Electrocardiogram in Hyperkalemia. — Steven H. Mitchell, William J. Brady The Electrocardiagram in Emergency and Acute Care. 2023.
19. Diabetic Ketoacidosis: Evaluation and Treatment. — Veauthier B, Levy-Grau B. American Family Physician. 2024.
20. Arterial Blood Gases and Acid-Base Regulation. — Sanghavi SF, Swenson ER. Seminars in Respiratory and Critical Care Medicine. 2023.
21. Extracorporeal Treatment for Ethylene Glycol Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. — Ghannoum M, Gosselin S, Hoffman RS, et al. Critical Care. 2023.
22. Recommendations for the Role of Extracorporeal Treatments in the Management of Acute Methanol Poisoning: A Systematic Review and Consensus Statement. — Roberts DM, Yates C, Megarbane B, et al. Critical Care Medicine. 2015.
23. FDA Drug Label. — Updated date: 2025-11-24. Food and Drug Administration.
24. Treatment of Acute Metabolic Acidosis. — Aamir N, Ralto KM. Current Opinion in Nephrology and Hypertension. 2025.
25. Extracorporeal Kidney-Replacement Therapy for Acute Kidney Injury. — Gaudry S, Palevsky PM, Dreyfuss D. The New England Journal of Medicine. 2022.